Illumina, Inc.
Stocks
Evergy, Inc.
Stocks
Illumina, Inc. vs Evergy, Inc.: A Data-Driven Comparison for Investors
Last updated: June 7, 2026
Summary
Illumina, Inc. and Evergy, Inc. operate in vastly different sectors with distinct financial profiles. While Illumina excels with a higher market cap and aggressive growth metrics in the healthcare diagnostics space, Evergy demonstrates stability with a lower beta and a solid dividend yield in the utility sector. This comparison provides expert insights into their financial health and investment potential.
Key Differences at a Glance
| Aspect | Illumina, Inc. | Evergy, Inc. | Winner |
|---|---|---|---|
| Market Capitalization | Approximately $24.56 billion | $19.19 billion | |
| Profit Margin | 19.4% | 14.6% | |
| Beta (Market Volatility) | 1.49 | 0.534 | |
| Dividend Yield | None | 3.34% | |
| Price-to-Earnings (PE) Ratio | 29.51 | 22.15 |
Market Capitalization: Illumina’s higher market cap indicates a larger market presence and investor confidence in its biotech and diagnostics innovations.
Profit Margin: Illumina’s superior profit margin suggests more efficient operations and higher profitability relative to revenue, despite industry differences.
Beta (Market Volatility): While Illumina’s higher beta reflects greater sensitivity to market swings in the healthcare sector, Evergy’s lower beta indicates stability typical of utility stocks. Both are appropriate depending on risk appetite.
Dividend Yield: Evergy offers a notable dividend yield of 3.34%, providing income stability, whereas Illumina does not pay dividends, favoring reinvestment for growth.
Price-to-Earnings (PE) Ratio: Evergy’s lower PE ratio suggests it may be undervalued relative to its earnings, potentially offering a more attractive valuation for value investors compared to Illumina’s higher PE.
Detailed Analysis
Illumina, Inc. operates within the healthcare diagnostics sector, characterized by rapid technological innovation and high growth potential. With a revenue of approximately $4.39 billion and a market cap nearing $24.56 billion, Illumina demonstrates a strong financial position driven by its leadership in genetic sequencing and research tools. Its EPS of $5.50 and profit margin of 19.4% highlight profitability and operational efficiency, crucial for investors assessing biotech stocks. The company’s beta of 1.49 indicates higher volatility, aligning with the biotech industry's inherent risks but also its growth prospects.
In contrast, Evergy, Inc., a utility company, has a revenue of around $6.03 billion and a market cap of nearly $19.19 billion. Its sector stability is reflected in its lower beta of 0.534, which appeals to risk-averse investors seeking consistent utility service providers. Evergy’s EPS of $3.76 and profit margin of 14.6% reveal steady operational performance, typical of regulated electric utilities. Its dividend yield of 3.34% underscores its income-generating capacity, making it attractive for income-focused portfolios.
The valuation metrics further differentiate the two entities. Illumina’s PE ratio of approximately 29.51 indicates higher valuation multiples, often justified by growth expectations in biotech. Conversely, Evergy’s PE of 22.15 suggests it may be undervalued relative to earnings, especially given its sector stability. The forward PE ratios also reinforce this, with Illumina at 27.41 and Evergy at 18.29, indicating growth prospects are more aggressively priced into Illumina’s shares.
Both companies exhibit strong fundamentals but cater to different investor profiles. Illumina’s innovative focus and higher growth metrics appeal to investors seeking capital appreciation in emerging biotech markets. On the other hand, Evergy’s stable dividend yield and lower volatility make it suitable for income and risk-averse investors. The absence of dividends in Illumina contrasts with Evergy’s consistent payout, emphasizing their distinct strategic priorities.
Overall, considering profit margins, market valuation, and sector characteristics, Illumina presents a higher growth but riskier profile, while Evergy offers stability and income. This detailed comparison aids expert investors in aligning their portfolio strategies with sector-specific dynamics and valuation insights.
Verdict
Illumina, Inc. emerges as the superior choice for growth-oriented investors seeking exposure to the high-potential biotech sector, given its higher market cap, profit margin, and growth valuation. However, for risk-averse investors prioritizing income and stability, Evergy, Inc. offers attractive dividends, lower volatility, and a compelling valuation profile. Ultimately, the decision hinges on individual risk tolerance and investment objectives, with Illumina excelling in growth metrics and Evergy leading in stability and income.
Who Should Choose What
Choose Illumina, Inc. if...
Best for investors focused on biotech innovation, high growth potential, and technological leadership in genetic research and diagnostics.
Choose Evergy, Inc. if...
Best for income-focused investors, risk-averse portfolios, and those seeking stable utility stocks with consistent dividends.